UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 337

Sortiert nach

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

Leukemia, 2021-06, Vol.35 (6), p.1722-1731

2021

Volltextzugriff (PDF)

Editorial: T-cell directed therapies in multiple myeloma

Frontiers in oncology, 2023-06, Vol.13, p.1206475-1206475

2023

Volltextzugriff (PDF)

Preface of the Special Issue “COVID-19 Infection and Hematological Malignancies”

Cancers, 2022-09, Vol.14 (18), p.4497

2022

Volltextzugriff (PDF)

Clinical Features and Risk Stratification of Multiple Myeloma Patients with COVID-19

Cancers, 2023-07, Vol.15 (14), p.3598

2023

Volltextzugriff (PDF)

Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma--A Unique Entity: A Report of Two Cases With Low-Level Bone Marrow Involvement and Review of the Literature

American journal of clinical pathology, 2020-12, Vol.154 (6), p.816-827

2020

Volltextzugriff (PDF)

A case of benign immunoglobulin D monoclonal gammopathy of undetermined significance with 26 years of follow‐up

EJHaem, 2024-02, Vol.5 (1), p.235-237

2024

Volltextzugriff (PDF)

Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel

Journal of hematology and oncology, 2024-06, Vol.17 (1), p.1-11

2024

Volltextzugriff (PDF)

Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group

Frontiers in health services, 2024-04, Vol.4, p.1354760-1354760

2024

Volltextzugriff (PDF)

Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study

British journal of haematology, 2024-06, Vol.204 (6), p.2227-2232

2024

Volltextzugriff (PDF)

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN

Blood cancer journal (New York), 2024-07, Vol.14 (1), p.107-10, Article 107

2024

Volltextzugriff (PDF)

Cardiovascular disease and chimeric antigen receptor cellular therapy

Frontiers in cardiovascular medicine, 2022-09, Vol.9, p.932347-932347

2022

Volltextzugriff (PDF)

Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel program

Contemporary clinical trials communications, 2024-06, Vol.39, p.101292-101292, Article 101292

2024

Volltextzugriff (PDF)

Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

American journal of hematology, 2021-06, Vol.96 (6), p.708-718

2021

Volltextzugriff (PDF)

Corrigendum to “The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement” [Leukemia Res. 100 (2021) 106480]

Leukemia research, 2021-05, Vol.104, p.106563-106563, Article 106563

2021

Volltextzugriff (PDF)

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

American journal of hematology, 2021-09, Vol.96 (9), p.1120-1130

2021

Volltextzugriff (PDF)

Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy

Hematological oncology, 2024-07, Vol.42 (4), p.e3293-n/a

2024

Volltextzugriff (PDF)

Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Transplantation and cellular therapy, 2022-09, Vol.28 (9), p.546-559

2022

Volltextzugriff (PDF)

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience

Transplantation and cellular therapy, 2024-08, Vol.30 (8), p.790.e1-790.e16

2024

Volltextzugriff (PDF)

P932: PATIENT PERSPECTIVES ON BCMA‐TARGETED THERAPIES FOR MULTIPLE MYELOMA: A SURVEY CONDUCTED IN A PATIENT ADVOCACY GROUP

HemaSphere, 2023-08, Vol.7 (S3), p.e17730f9-n/a

2023

Volltextzugriff (PDF)

S193: BMS‐986393 (CC‐95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T‐CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY

HemaSphere, 2023-08, Vol.7 (S3), p.e9863287-n/a

2023

Volltextzugriff (PDF)

Abstract CT034: A phase I study of GSK2857916, a BCMA-directed monoclonal antibody conjugated to microtubule-disrupting agent in patients with relapsed, refractory multiple myeloma and other BCMA-expressing hematologic malignancies

Cancer research (Chicago, Ill.), 2016-07, Vol.76 (14_Supplement), p.CT034-CT034

2016

Volltextzugriff (PDF)

1 – 25 von 337

Suche als RSS-Feed

Aktive Filter

KollektionTaylor & Francis:Master (3349 titles)

ThemaAnimals

ThemaHumans

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(279)
Mit Volltextzugriff
(304)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(335)
Japanisch
(22)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse

Editorial: T-cell directed therapies in multiple myeloma

Preface of the Special Issue “COVID-19 Infection and Hematological Malignancies”

Clinical Features and Risk Stratification of Multiple Myeloma Patients with COVID-19

Lenalidomide-Associated Secondary B-Lymphoblastic Leukemia/Lymphoma--A Unique Entity: A Report of Two Cases With Low-Level Bone Marrow Involvement and Review of the Literature

A case of benign immunoglobulin D monoclonal gammopathy of undetermined significance with 26 years of follow‐up

Impact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel

Patient perspectives on BCMA-targeted therapies for multiple myeloma: a survey conducted in a patient advocacy group

Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study

Daratumumab in transplant-eligible patients with newly diagnosed multiple myeloma: final analysis of clinically relevant subgroups in GRIFFIN

Cardiovascular disease and chimeric antigen receptor cellular therapy

Transferring care to enhance access to early-phase cancer clinical trials: Protocol to evaluate a novel program

Health‐related quality of life in transplant‐eligible patients with newly diagnosed multiple myeloma treated with daratumumab, lenalidomide, bortezomib, and dexamethasone: Patient‐reported outcomes from GRIFFIN

Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma

Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee

Corrigendum to “The association of leukocyte immunoglobulin-like receptor subfamily B-4 expression in acute myeloid leukemia and central nervous system involvement” [Leukemia Res. 100 (2021) 106480]

Addition of daratumumab to lenalidomide, bortezomib, and dexamethasone for transplantation-eligible patients with newly diagnosed multiple myeloma (GRIFFIN): final analysis of an open-label, randomised, phase 2 trial

Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk

Outcomes of therapeutic plasma exchange for the treatment of patients with multiple myeloma cast nephropathy

Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy

Peripheral neuropathy symptoms, pain, and functioning in previously treated multiple myeloma patients treated with selinexor, bortezomib, and dexamethasone

Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The US Myeloma Immunotherapy Consortium Real- World Experience

P932: PATIENT PERSPECTIVES ON BCMA‐TARGETED THERAPIES FOR MULTIPLE MYELOMA: A SURVEY CONDUCTED IN A PATIENT ADVOCACY GROUP

S193: BMS‐986393 (CC‐95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP 5 MEMBER D (GPRC5D)–TARGETED CAR T‐CELL THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1 STUDY

Abstract CT034: A phase I study of GSK2857916, a BCMA-directed monoclonal antibody conjugated to microtubule-disrupting agent in patients with relapsed, refractory multiple myeloma and other BCMA-expressing hematologic malignancies

Aktive Filter

Suchergebnisse filtern